<LA-GLP/GIP/GCG, HM15275>
First patient dosed Dec. 26, 2025
Phase 2 expected to conclude in first half of 2027
Aims for ≥25% weight reduction, accelerated commercialization
Indication expansion to diabetes planned
(February 2, 2026) Hanmi’s next-generation triple agonist obesity therapy (LA-GLP/GIP/GCG, HM15275)―expected to deliver ≥25% weight reduction while minimizing muscle loss―has been progressing smoothly through its clinical stage in the United States since entering Phase 2.
Hanmi Pharmaceutical, the core operating subsidiary of Hanmi Science, announced on the February 2 that it completed dosing of the first patient within approximately three months after receiving FDA clearance for Phase 2 development (IND) in September 2025.
Jae-hyun Park, CEO of Hanmi Pharmaceutical, said, “HM15275, our next-generation long-acting GLP-1/GIP/GCG triple-agonist candidate, moved into Phase 2 with strong momentum―reaching first patient dosing within a relatively short period following FDA clearance.” He added, “Leveraging Hanmi’s differentiated innovation and R&D capabilities, we will further accelerate the development of innovative medicines and continue strengthening our position as a global top-tier company.”
The Phase 2 trial will focus on validating differentiated efficacy over 36 weeks of long-term dosing, including weight reduction in patients with obesity and severe obesity, as well as improvements in lean mass. Since initiation, patient enrollment has been proceeding smoothly, and recruitment is expected to gain further momentum―accelerating overall clinical progress.
Phase 2 completion is expected in the first half of 2027, and Hanmi plans to drive clinical development with speed toward a 2030 commercialization goal. If Phase 2 continues to advance as planned, analyses indicate HM15275 has strong potential to move beyond the limitations of existing GLP-1 based therapies and emerge as a ‘Best-in-Class’ option for patients with severe obesity.
In parallel, Hanmi plans to expand HM15275’s indications beyond obesity into the diabetes treatment area. On January 2, 2026, the company also received FDA clearance for Phase 2 development (IND) to evaluate efficacy endpoints including glycemic control in patients with diabetes, and plans to initiate the trial within the first half of this year.
Dr. Moon Hee Lee, Head of the clinical team at Hanmi Pharmaceutical, said, “After securing encouraging results in Phase 1, we rapidly moved Phase 2 of HM15275 onto the right track,” adding, “Through long-term dosing in Phase 2, we expect to more clearly demonstrate its competitiveness as a Best-in-Class obesity therapy.”
HM15275 is drawing strong expectations as the second pipeline asset in Hanmi’s obesity drug project, H.O.P (Hanmi Obesity Pipeline), which aims to carry forward the innovation of ‘efpeglenatide,’ targeted for launch in Korea in the second half of this year.
Precisely designed based on Hanmi’s extensive incretin research expertise, the triple agonist HM15275 is characterized by an optimized balance of GLP-1, GIP, and glucagon (GCG) receptor activation, enabling efficacy in obesity as well as various metabolic diseases.
GLP-1 receptor agonism increases satiety to reduce body weight and improves insulin secretion and sensitivity, supporting glycemic control. GIP enhances the pharmacological benefits of GLP-1 receptor agonism while helping alleviate common gastrointestinal adverse events such as nausea, vomiting, and diarrhea. Glucagon contributes not only to satiety regulation but also to energy expenditure and lipid metabolism.
According to Hanmi, appropriately leveraging these three pharmacological actions can maximize therapeutic potential not only for obesity, but also for type 2 diabetes and cardiovascular disease. In particular, HM15275 targets weight reduction of up to 25%, aiming to surpass bariatric surgery. In addition, by minimizing muscle loss through mechanisms that optimize metabolism, it is expected to deliver improved ‘weight loss quality.’
Currently, GLP-1 based drugs semaglutide (Wegovy) and tirzepatide (Mounjaro) have demonstrated approximately 15~20% weight reduction in obesity clinical studies; however, unmet needs remain because they have not reached bariatric surgery-level weight reduction (25~30%).
In particular, as next-generation triple agonist development accelerates across the global biopharmaceutical industry, the importance of new approaches combining three distinct pharmacological mechanisms is becoming even more prominent.
In-Young Choi, Head of Hanmi’s R&D Center, said, “Targeting the global obesity market, HM15275 will establish itself as Best-in-Class in obesity treatment based on ≥25% weight reduction that surpasses surgical therapy―even with non-invasive treatment alone,” adding, “Hanmi’s obesity novel drug ‘H.O.P (Hanmi Obesity Pipeline)’ project is a full-lifecycle, tailored portfolio, and its outcomes are becoming visible one by one.”
He added, “Through new mechanisms and differentiated development strategies to overcome the limitations of existing therapies, we will leap forward as a ‘global frontier’ leading the worldwide obesity treatment paradigm, and by uniting company-wide capabilities, we will achieve successful commercialization.”